Skip to main content
Clinical Trials/NCT03870074
NCT03870074
Completed
Not Applicable

Cardiopulmonary Exercise Test Predicts Long-term Survival and Positive Response to Cardiac Resynchronization Therapy.

National Institute of Cardiology, Warsaw, Poland0 sites122 target enrollmentOctober 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure With Reduced Ejection Fraction
Sponsor
National Institute of Cardiology, Warsaw, Poland
Enrollment
122
Primary Endpoint
Death
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The study tested the usefulness of cardiopulmonary exercise test (CPET) in selection of potential responders to CRT.

Detailed Description

Cardiac resynchronization therapy (CRT) is an acknowledged therapy of selected patients with heart failure (HF). One of the unresolved problems is high percentage of non-responders to CRT, reaching 40%. No single parameter, helpful in identifying non-responders prior to CRT implantation, was found. The study included patients with HF of ischemic or non-ischemic etiology, in NYHA class II-IV, EF≤35% and QRS≥120ms. All the patients had CRT implanted. Clinical evaluation, CPET and NT-proBNP levels measurement were performed before CRT implantation and after 3-6 months. Improvement in HF symptoms of one or more NYHA class correlated with two-years survival. It was used as the criterion of positive response to CRT.

Registry
clinicaltrials.gov
Start Date
October 2009
End Date
October 2017
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
National Institute of Cardiology, Warsaw, Poland
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • HF in class III or IV according to New York Heart Association (NYHA) in the course of ischemic (ICM) or non-ischemic cardiomyopathy (NICM), QRS complex duration ≥ 120ms, EF ≤35% and dilatation of the left ventricle diastolic diameter \>55mm (LVdD), according to the ESC guidelines in 2007
  • HF in NYHA class II, LBBB with QRS complex duration ≥ 150 ms according to the guidelines update in 2010
  • optimal pharmacotherapy of HF in the period of three months prior to the study entry.
  • the expected survival of the patient \> 1 year.

Exclusion Criteria

  • severe chronic obstructive pulmonary disease (FEV1 \<30%)
  • inability to perform a stress test on a treadmill

Outcomes

Primary Outcomes

Death

Time Frame: Follow up within 5 years from CRT

All cause death, data from hospital entries and phone follow-up .

Heart transplantation

Time Frame: Follow up within 5 years from CRT

Heart transplantation as the definitive therapy of end-stage heart failure.

Secondary Outcomes

  • Positive response to CRT(Follow up within 1 year from CRT)

Similar Trials